Choosing between a clinical positioning and a clean positioning is not a branding exercise — it is an evidence decision you make before the brief is written. A clinical route commits you to finished-product testing, dermatological supervision records, and instrumented or consumer data on the actual formula in the actual pack. A clean route commits you to ingredient disclosure, supplier declarations, certification backing, and a published standard you are willing to defend line by line. Body care makes both routes harder than facial skincare: rinse-off versus leave-on changes the exposure logic, high-water formulas change the preservation logic, low-pH actives change the packaging compatibility logic, and fragrance load changes both the allergen declaration and the bottle. This guide sets out what a body care OEM manufacturer can realistically put in your hands for each route, what to ask for by name, and where projects of this type most often stall.
TL;DR — the 60-second decision brief
- What triggers the requirement: Any claim on pack, PDP, or ad — “dermatologist tested”, “clinically proven”, “suitable for sensitive skin”, “vegan”, “fragrance-free”, “clean” — is a substantiation obligation in the US and an “adequate and verifiable evidence” obligation in the EU. Body care claims sit close to the cosmetic/drug line because consumers read them as skin-treatment claims.
- Decide three things first: (1) which single positioning route you are funding — clinical, clean-transparency, or a hybrid with a clear hierarchy; (2) whether your hero claim is a finished-product claim or an ingredient-story claim; (3) whether you will publish a written definition of “clean” before artwork is approved.
- Fastest safe path: lock claim architecture and packaging format first, then run stability, micro, and compatibility in parallel with one finished-product study. Optimize fragrance, texture, and secondary claims later — they can move without invalidating the dossier.
- Request these five items immediately: finished-product stability protocol and report, preservative efficacy (challenge test) report, packaging compatibility assessment for the exact pack, claim substantiation study protocol with sample size and endpoints, and a full documentation pack (COA, SDS, INCI/allergen declaration, natural-origin calculation if used).
- Do not accept: an ingredient clinical paper presented as proof of a finished-product claim, or “clean” with no written definition behind it.
Informational only, not legal advice. Final claim wording and label compliance should be confirmed with your regulatory or legal counsel for each market.
Decision tree: classify your situation before you brief
- Start here — is your hero claim about what the product does, or about what it does not contain? If it is about what it does (“72-hour hydration”, “visibly smoother skin”, “suitable for sensitive skin”), go to step 2. If it is about absence (“free-from”, “clean”, “non-toxic”), go to step 4.
- Do you want to say “clinically proven” or “dermatologist tested”? If yes, require a finished-product study report naming the tested formula, batch, subject count, duration, endpoints, and the dermatologist’s role. If the answer is only an ingredient study, downgrade the wording to an ingredient-context statement — do not let it become a product claim.
- Is the claim rinse-off or leave-on? Leave-on body lotions, butters, and oils carry higher exposure and higher irritation sensitivity — budget for patch/HRIPT and a defined sensitive-skin population. Rinse-off washes still need preservative efficacy and compatibility data.
- Are you prepared to publish your clean standard? If yes, proceed: define excluded and included ingredient classes, publish the rationale, and collect supplier declarations for every minor ingredient. If no, do not use “clean” as a lead claim — use specific, provable statements instead.
- Is any wording drug-adjacent? “Treats eczema”, “repairs the skin barrier”, “heals”, “restores” can move a cosmetic into drug or therapeutic territory depending on market. If your copy depends on that language, stop and route it to regulatory review before sampling.
- Boundary cases: markets outside the US/EU (AICIS in Australia, ASEAN, Gulf), OTC/drug-adjacent categories, products making environmental claims, and any claim supported only by supplier marketing material — all require specialist review and, usually, additional testing.
What each positioning route actually commits you to
| Positioning route |
Typical consumer-facing claims |
Evidence a body care OEM can supply |
Where it usually breaks |
| Clinical / derm-oriented |
Dermatologist tested, clinically tested, suitable for sensitive skin, 24/48/72-hour hydration |
Finished-product study protocol and report, dermatologist supervision record, instrumental measures (e.g., corneometry, TEWL), patch/HRIPT report |
Ingredient paper presented as product proof; “reviewed by a dermatologist” relabelled as “tested” |
| Clean / transparency |
Vegan, cruelty-free, fragrance-free, X% natural origin, free-from [named ingredient class] |
Full INCI and EU allergen declaration, supplier declarations, vegan/cruelty-free certification, natural-origin calculation, fragrance allergen statement |
Undefined “clean”; “chemical-free” or “non-toxic” wording; cross-contamination on shared lines |
| Performance-led (hybrid) |
Visibly firmer-looking skin, smoother texture, reduced appearance of dryness |
Finished-product instrumental or consumer study with defined population and endpoints |
Borrowing efficacy language from an active’s supplier brochure |
The minimum evidence pack to request from a manufacturer
Send this list as written. A manufacturer with a mature body care dossier can answer most of it within days; vague or partial answers are your earliest risk signal.
A) Compliance and filings
- Request: Confirmation of the regulatory route for each target market and who holds the Cosmetic Product Safety Report (EU/UK).
Evidence: Signed CPSR with named assessor, plus notification reference where applicable.
Owner: Manufacturer / Safety assessor.
Acceptance criteria: CPSR issued against the final formula and final packaging, not a generic base.
- Request: Written statement of how the product is classified (cosmetic vs drug/therapeutic) in each market, with the reasoning for any borderline claim.
Evidence: Regulatory memo or claim decision log.
Owner: Manufacturer regulatory + Buyer.
Acceptance criteria: Every hero claim has a written classification decision attached.
- Request: Responsible person / agent details and label entity information.
Evidence: Label pack showing legal entity, address, batch code, PAO or best-before.
Owner: Buyer / Manufacturer.
Acceptance criteria: Artwork approved against a market-specific label checklist.
B) Testing and substantiation
- Request: Finished-product stability data (accelerated and real-time) covering the exact pack, closure, and filling format.
Evidence: Report with batch number, storage conditions, timepoints, and measured results versus specification.
Owner: Manufacturer / Lab.
Acceptance criteria: Minimum 12-week accelerated data with no out-of-spec result; real-time study with stated review dates.
- Request: Preservative efficacy (challenge) test on the finished formula.
Evidence: Report naming the test method, organisms, and log reductions at each interval.
Owner: Lab.
Acceptance criteria: Pass against the method’s criteria for the product’s category, with the marketed pack and typical use conditions stated.
- Request: Packaging compatibility assessment — product-to-pack contact, closure torque, drop/leak, and compatibility of fragrance and actives with the chosen resin and liner.
Evidence: Compatibility report plus supplier material declaration (resin, liner, recycled content, food/contact suitability).
Owner: Manufacturer / Packaging supplier.
Acceptance criteria: Tested with the actual formula at the actual viscosity and fill temperature; leak and drop results within agreed limits.
- Request: Claim substantiation study for the specific wording you intend to use.
Evidence: Protocol (objective, population, sample size, duration, endpoints, statistical plan) plus final report — for the finished product, not the raw material.
Owner: Lab / Manufacturer.
Acceptance criteria: Report names the tested formula and batch, and the endpoint supports the exact consumer wording.
- Request: Patch test or HRIPT for a “suitable for sensitive skin” or “dermatologist tested” position.
Evidence: Report with dermatologist name, role, dates, and adverse-event record.
Owner: Lab / Dermatologist.
Acceptance criteria: The dermatologist’s actual role is documented and matches the wording you will print.
C) Labeling and claim guardrails
- Request: Full INCI as it will appear on pack, plus EU fragrance allergen declaration and any market-specific restrictions.
Evidence: Ingredient declaration sheet cross-checked against the formula bill of materials.
Owner: Manufacturer / Regulatory.
Acceptance criteria: Ingredient order and naming match the formula version that will be produced.
- Request: Written support for every “free-from”, “vegan”, “natural origin”, or percentage claim.
Evidence: Supplier declarations for each input, certification certificates, and a calculation sheet for percentage claims.
Owner: Manufacturer / Ingredient suppliers.
Acceptance criteria: Every claim on the artwork maps to a document in the pack; no claim relies on a supplier brochure alone.
- Request: A written definition of your “clean” standard, drafted by you and validated against the formula by the manufacturer.
Evidence: One-page published standard plus a formula compliance matrix showing each ingredient against the standard.
Owner: Buyer (definition) / Manufacturer (verification).
Acceptance criteria: Every ingredient is classified pass/fail with rationale and no undisclosed exception.
- Request: Cross-contamination and changeover controls if “free-from” claims matter.
Evidence: Line changeover procedure and, where relevant, cleaning verification records.
Owner: Manufacturer.
Acceptance criteria: Documented changeover steps with verification evidence for the specific production line.
D) QA, traceability, and audit readiness
- Request: Certificate of Analysis and Safety Data Sheet per batch.
Evidence: COA with tested parameters and results, SDS current for the marketed formula.
Owner: Manufacturer.
Acceptance criteria: COA issued against your specification and referencing the production batch code.
- Request: Batch record and raw material traceability for a pilot or first production lot.
Evidence: Batch manufacturing record with lot numbers of each input and reconciliation.
Owner: Manufacturer.
Acceptance criteria: Full traceability from finished batch back to raw material lots, retrievable within 24 hours.
- Request: Quality system and audit standing.
Evidence: Current GMP/ISO certificate, most recent audit summary, and deviation/CAPA sample.
Owner: Manufacturer.
Acceptance criteria: Certificate valid at time of shipping; deviations documented and closed.
Evidence pack summary — one line each
- Finished-product stability report (accelerated + real-time) against the exact pack.
- Preservative efficacy / challenge test report for the shipped formula.
- Packaging compatibility report with supplier material declaration.
- Finished-product claim substantiation report (protocol + results).
- Patch test / HRIPT report with named dermatologist and role.
- Full INCI, EU allergen declaration, and market restriction check.
- Supplier declarations and certifications backing vegan, cruelty-free, natural-origin claims.
- Written “clean” standard plus formula compliance matrix.
- Cosmetic Product Safety Report issued against the final formula and pack.
- Batch-specific COA and current SDS.
- Batch manufacturing record with raw material traceability.
- GMP/ISO certificate and audit summary.
Realistic timeline: fastest safe path versus standard path
| Phase |
Buyer action |
Manufacturer action |
Evidence output |
| 1. Claim architecture (week 0–1) |
Lock the one hero claim, list every secondary claim, confirm target markets |
Flag borderline wording; confirm regulatory route per market |
Claim decision log with classification per claim |
| 2. Formula and packaging lock (week 1–4) |
Choose format, fill size, closure type, and decoration method |
Bench samples, viscosity target, compatibility screening with the chosen pack |
Approved master formula and packaging specification |
| 3. Stability, micro, compatibility (week 3–10) |
Approve test plan and acceptance criteria before testing starts |
Run accelerated stability, challenge test, and pack compatibility in parallel |
Stability report, challenge test report, compatibility report |
| 4. Claim substantiation (week 4–14) |
Approve protocol wording so the endpoint matches the printed claim |
Commission and manage the study; hold the dermatologist record |
Final study report naming formula and batch |
| 5. Label and claims review (week 8–12) |
Submit artwork, ingredient declaration, and claim substantiation references together |
Label review against market checklist; flag unsupported wording |
Signed-off artwork and label review record |
| 6. Pilot / first production (week 10–14) |
Approve pilot samples against the specification, not against a feeling |
Pilot run, fill and closure trial, retain samples |
Pilot report, retained samples, COA |
| 7. Documentation handoff (week 14–16) |
File the full dossier per SKU and per market |
Release COA, SDS, CPSR, batch record, and traceability pack |
Complete release dossier |
Fastest safe path (compress 3–4 weeks): compress by running stability, micro, and compatibility simultaneously on the same batch, by selecting a proven base and pack combination rather than a new mould, and by limiting yourself to one finished-product study supporting one hero claim. What you may compress: secondary claims, fragrance refinement, decoration changes. What you may not compress: the challenge test, the compatibility test, or the gap between label approval and first production.
Standard path (lower risk): allow extra weeks for a new mould or pump, for real-time stability before first shipment to a market that expects it, and for a second claim study if your copy uses two independent efficacy statements.
Where body care projects fail: eight failure modes
- Symptom: Pump or disc-top seizes, leaks, or dispenses unevenly after two weeks of transit.
Root cause: The formula’s viscosity and surfactant load were never tested with the chosen dispenser; compatibility was assessed on water only.
Prevention: Require compatibility testing with the finished formula at production viscosity and fill temperature.
What to request from factory (evidence): Packaging compatibility report plus drop/leak test results for the exact pack.
- Symptom: Label lifts at the shoulder of a curved HDPE bottle; fragrance smell migrates through the print.
Root cause: Adhesive and film selected without considering resin type, surface energy, oil content, or fragrance-plastic interaction.
Prevention: Test decoration on filled, aged bottles rather than flat panels; confirm adhesive and film against the resin.
What to request from factory (evidence): Decoration adhesion test report and packaging supplier material declaration after accelerated aging.
- Symptom: COA, SDS, or stability report is missing or arrives after the container ships.
Root cause: Documentation treated as an administrative afterthought with no owner and no release gate.
Prevention: Make the dossier a shipping condition, not a follow-up request.
What to request from factory (evidence): A signed documentation matrix confirming each document, its version, and its issue date before release.
- Symptom: Ingredient list on pack does not match the manufactured formula.
Root cause: Formula revision after artwork approval, or a base change without re-issuing the declaration.
Prevention: Tie artwork approval to a formula version number and re-check on any change.
What to request from factory (evidence): Ingredient declaration cross-checked against the controlled bill of materials with version numbers.
- Symptom: “Clinically proven” appears on pack, but the only study is on a raw material.
Root cause: Ingredient research treated as finished-product evidence — a persistent and avoidable error, since ingredient is not the same as finished product.
Prevention: Separate ingredient stories from product claims in your claim log and require the study to name the tested formula.
What to request from factory (evidence): Study protocol and report identifying the tested product, batch, subjects, endpoints, and statistical analysis.
- Symptom: “Dermatologist tested” is challenged because the dermatologist only reviewed the file.
Root cause: The wording overstates the professional’s actual involvement.
Prevention: Match wording to involvement — reviewed, supervised, or tested are not interchangeable.
What to request from factory (evidence): Signed statement of the dermatologist’s role, dates, and scope of participation.
- Symptom: “Free-from” claim undermined by a shared line or a minor ingredient.
Root cause: No changeover verification and no supplier declaration for minor inputs such as glycerin or stearic acid.
Prevention: Map every claim to a document at the ingredient level, including minors.
What to request from factory (evidence): Supplier declarations per input and documented line changeover verification.
- Symptom: Viscosity drops or pH drifts by week eight; the texture no longer matches the approved sample.
Root cause: Stability questioned late, or a chelator/preservative choice that interacts with a low-pH active in a high-water body wash.
Prevention: Set acceptance criteria before testing starts and freeze the formula before the pilot run.
What to request from factory (evidence): Accelerated stability report with measured viscosity and pH at each timepoint versus specification.
Red lines: what not to cut
- Do not cut the preservative efficacy test on a high-water body wash or lotion, even on a compressed timeline.
- Do not cut pack compatibility testing to hit a launch date; a leaking pump costs more than a delayed run.
- Do not cut finished-product substantiation in favour of an ingredient study for any efficacy claim.
- Do not cut supplier declarations for vegan, cruelty-free, or natural-origin claims — one undeclared minor input invalidates the claim.
- Do not cut the written definition of “clean”; an undefined claim cannot be defended and invites competitor challenge.
Copy-paste checklist: send this to your supplier today
Share: target markets and intended channel (US / EU / other) in writing.
Confirm: cosmetic vs drug-adjacent classification for each hero claim.
Provide: finished-product stability report for the exact pack and closure.
Provide: preservative efficacy (challenge) test report for the shipped formula.
Provide: packaging compatibility report, including fragrance-plastic interaction.
Confirm: packaging supplier declaration (resin, liner, recycled content).
Attach: full INCI and EU fragrance allergen declaration, version-controlled.
Attach: supplier declarations for every "free-from", vegan, and natural-origin claim.
Share: natural-origin calculation sheet if a percentage claim is used.
Provide: finished-product claim substantiation protocol for our review before testing.
Confirm: tested formula and batch will be identified in the study report.
Provide: patch test or HRIPT report with dermatologist name and role.
Confirm: wording matches the dermatologist's actual level of involvement.
Attach: Cosmetic Product Safety Report issued against the final formula and pack.
Provide: claimed benefit vs tested endpoint mapping for every on-pack claim.
Confirm: line changeover and cleaning verification if free-from claims apply.
Provide: batch-specific COA and current SDS with the shipment.
Provide: batch manufacturing record and raw material traceability on request.
Attach: GMP/ISO certificate and latest audit summary.
Lock: formula version and artwork version before pilot production.
Approve: pilot samples against written specification, not preference.
Review: label pack against our market checklist before mass production.
Schedule: documentation handoff date as a release condition.
Confirm: 24-hour retrieval time for traceability records.
Summary table: levers, red lines, and evidence
| Lever / Decision |
Primary impact |
What to do (specific) |
Do NOT cut (red line) |
Evidence needed (request) |
Expected timeline effect |
| Positioning route |
Determines the entire testing budget |
Pick clinical, clean-transparency, or hybrid, and rank claims by defensibility |
Finished-product substantiation for any efficacy claim |
Claim decision log with market classification per claim |
Adds 1 week up front; prevents 4–6 weeks of rework |
| “Clean” definition |
Makes an undefendable claim defensible |
Publish a one-page standard and map every ingredient against it |
Written standard plus ingredient-level compliance matrix |
Formula compliance matrix with pass/fail rationale |
1–2 weeks before artwork lock |
| Hero claim selection |
Controls study design and cost |
Limit to one efficacy claim supported by one finished-product study |
Study naming the tested formula and batch |
Protocol with population, endpoints, and statistical plan |
Saves 2–4 weeks versus two parallel studies |
| Pack format |
Drives compatibility risk and lead time |
Use a proven bottle-pump combination for launch; move to custom after validation |
Compatibility test with the real formula at production viscosity |
Compatibility report plus drop/leak results |
Custom moulds add 6–10 weeks; stock packs add days |
| Preservation strategy |
Prevents micro failure after launch |
Run the challenge test on the final formula, not a bench prototype |
Preservative efficacy test on the shipped formula |
Challenge test report with organisms and log reductions |
4–6 weeks; cannot be parallelized away |
| Stability programme |
Protects texture, pH, and shelf-life claims |
Set acceptance criteria before testing and freeze the formula at pilot |
12-week accelerated data with no out-of-spec result |
Stability report with timepoint measurements vs specification |
10–12 weeks; overlaps with compatibility testing |
| Dermatologist involvement |
Determines whether “derm tested” wording is usable |
Agree the exact role in writing before the study begins |
Signed statement of role, dates, and scope |
Dermatologist statement plus study report |
2–4 weeks; wording changes may remove the need entirely |
| Free-from and vegan claims |
Prevents claim invalidation post-launch |
Collect declarations for every input, including minors, and verify changeover |
Ingredient-level supplier declarations |
Declaration pack plus changeover verification records |
2–3 weeks of supplier chasing if started late |
| Documentation handoff |
Controls release and audit readiness |
Make the dossier a shipping condition with a named owner on both sides |
Complete dossier before container release |
COA, SDS, CPSR, batch record, traceability pack |
Sets release date; prevents post-shipment holds |
FAQ
Can we call a product “clean” without defining it?
You can print the word, but you cannot defend it. “Clean” is not a legal safety category, and consumer trust in the term has been weakening because definitions vary so widely. The workable approach is to publish your own standard — what is excluded, what is included, and why — and have the manufacturer verify each ingredient against it. Avoid implying that legally permitted ingredients are unsafe; that framing invites both regulatory scrutiny and consumer scepticism.
Can an ingredient clinical study support a “clinically proven” finished-product claim?
No. An ingredient is not the finished product: concentration, interactions, and the use environment differ from the raw-material study. Ingredient research can support a carefully contextualised ingredient statement, but the moment you connect it to a product benefit you have created a finished-product claim that needs finished-product evidence. In the US this is also an implied-claim risk, because consumers will read “clinically tested ingredient” as a statement about the product.
What is the minimum evidence for a “suitable for sensitive skin” body lotion?
Define the population and test conditions first, then support them: a patch test or HRIPT on the finished formula, a documented dermatological role, and a consumer or instrumental study on the stated endpoints. A single patch test does not automatically make a product hypoallergenic, and “hypoallergenic” itself needs market-specific support. Treat “sensitive skin suitable” as a defined, tested claim rather than a general descriptor.
Are “chemical-free”, “non-toxic”, or “natural” safe to print?
“Chemical-free” is technically inaccurate for any cosmetic and risks being read as misleading; “non-toxic” implies a safety judgment about competing products that you would have to substantiate. “Natural” is not a safety grade and should not imply greater safety. If you want a transparency position, use specific, verifiable statements — named ingredients, percentages with a calculation sheet, certification-backed vegan or cruelty-free claims — rather than absence-based fear framing.
What information gets us a faster, more accurate quote?
Target markets, SKU count and formats (rinse-off or leave-on, fill size), positioning route and hero claim, packaging direction including closure type, and your launch window. With those five inputs a manufacturer can scope testing, flag claim risk, and give you a timeline that reflects real lead times rather than a best case.
Next step
If you are deciding between a clinical and a clean-transparency route for a body care line, send us your claim list and target markets first — we will return a claim risk map, a testing scope, and a timeline with dependencies named. Request a Quote and include your target markets, SKUs and formats, positioning, packaging direction, and launch window to get a faster, more precise response.
LAEYO
Hi, I'm your LAEYO representative, hope you like this blog post.
With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.